Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano, MD, James E. Herndon, PhD, Mark A. Socinski, MD, Xiaofei Wang, PhD, Dorothy Watson, Everett Vokes, MD, Mark R. Green, MD Journal of Thoracic Oncology Volume 3, Issue 2, Pages 158-162 (February 2008) DOI: 10.1097/JTO.0b013e318161225e Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 1 Median overall survival (A) and median progression-free survival (B). The median progression-free survival was 3.7 months, median survival was 9.2 months. The 1-year progression-free survival was 17% and the 1-year overall survival rate was 36%. Journal of Thoracic Oncology 2008 3, 158-162DOI: (10.1097/JTO.0b013e318161225e) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions